TORONTO–(BUSINESS WIRE)–Swift Medical, a digital health technology company focused on improving clinical and economic outcomes in chronic and acute wound care, has appointed Neil Sharma as its new Chief Commercial Officer, and Joseph Filippoli as its new Chief Information Officer, effective immediately.

Sharma is a seasoned global business leader and change agent with deep experience driving successful go-to-market strategies for corporate and startup technology-led business across the digital health ecosystem. Most recently, Sharma served as Executive Vice President at Sword Health, a trailblazer in digital physical therapy that Sharma helped scale to a $1.8B valuation. Prior to that, he held leadership positions at Accolade Health (personalized care delivery navigation and advocacy), nuVizz (hospital system logistics), and Pinn (healthcare cybersecurity). Sharma is also credited with pioneering Microsoft’s entry into mobile digital media and running the largest P&L at Samsung Mobile.

Filippoli brings over three decades of experience leading healthcare technology enterprises, driving technology innovation, operational efficiency and bottom-line profitability. Prior to Swift, Filippoli served as the founding Chief Information Officer at Tabula Rasa HealthCare (clinical pharmacy). He also formerly served as the Information Technology Health System Director at Children’s Hospital of Philadelphia. Additionally, Filippoli helped found the successful high growth startup ExcelleRx, Inc.

“It is my great pleasure to welcome these two digital health powerhouses to continue propelling Swift’s growth strategy and expansion into new markets,” said Brian Litten, CEO of Swift. “Neil and Joe both have successful track records of scaling innovative healthcare companies and driving adoption of new technologies. Together, we can continue to revolutionize wound care for the millions of patients and providers in need.”

Chronic wounds are the leading risk factor for hospitalizations, with almost 20% of the Medicare population experiencing a chronic wound at any given time. Conservative estimates for the yearly cost of wound care in the U.S. is more than $67B, which is estimated to rise to $82B by 2030 with the increased rates of chronic diseases, like diabetes, and an aging population.

“Swift is the leading clinically driven wound care imaging and documentation software solution in the market today with more than 20 peer reviewed publications, the most in its category,” said Neil Sharma, CCO of Swift Medical. “It is uniquely positioned to support clinicians who are serving this growing, high-risk population and I look forward to accelerating the company’s mission to provide high-quality patient-centric care to improve clinical and operational outcomes.”

Filippoli is currently directing Swift’s Information Technology enterprise, including overseeing Swift’s platform upgrade to optimize service, security and interoperability for current customers and the largest payers and risk-bearing providers.

“With the evolving healthcare landscape, our platform must exceed the expectations of providers across the care continuum today and tomorrow. It is my mission to deliver on that commitment,” said Joe Filippoli, CIO of Swift Medical.

About Swift Medical

Swift Medical is the global leader in digital wound care. We are headquartered in Toronto, with operations expanding across the U.S. and Canada. Our mission is to make empathy-driven wound care ubiquitous through AI-powered diagnostic technology. We are the trusted wound technology partner of more than 4,000 healthcare facilities in North America across the continuum of care and approximately 20,000 nurses and doctors use our platform each month. More than 20 million wound images and 40 million assessments have been captured through the app, which has empowered healthcare providers to deliver standardized, accessible and equitable wound care for every patient – with advanced, high-precision imaging, compliant documentation, clinical analytics and remote care. To learn more about Swift Medical, visit us at www.swiftmedical.com.

Contacts

Media
Kristen Abel
416-949-9159
kristen.abel@swiftmedical.com

DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Stephen (Steve) H. Rusckowski, former chairman, president and chief executive officer of Quest Diagnostics, Inc., to its board of directors. Effective today, Mr. Rusckowski serves on Baxter’s Compensation and Human Capital, and Quality, Compliance and Technology Committees. In addition, the company has announced that Michael (Mike) Mahoney will be resigning from the board effective Sept. 13, 2023, following nearly eight years of service.

“We are pleased to welcome Steve to Baxter’s board,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “His exemplary operational expertise, track record as a transformational leader, and distinguished career as a strategic operational executive will enhance our current board membership. I’m confident Steve’s patient-centric approach will further advance our Mission to Save and Sustain Lives.”

Added Almeida, “I also want to thank Mike for his many contributions to the Baxter board over his eight-year tenure. His extensive insight into the medical device industry and deep leadership experience have helped guide Baxter’s ongoing transformation, including our current strategic actions to drive greater growth, innovation and performance.”

About Steve Rusckowski

Mr. Rusckowski most recently served as chairman, president and chief executive officer of Quest Diagnostics, Inc. Prior to joining Quest Diagnostics, he was CEO of Philips Healthcare, and earlier in his career held roles of increasing responsibility at Hewlett-Packard Company and Procter & Gamble Company. Mr. Rusckowski currently serves as a director of Tenet Healthcare Corporation and Qiagen Inc. and previously served as a member of the boards of directors of Xerox Holdings Corporation, Covidien plc and MedQuist, Inc. He earned a bachelor’s degree in mechanical engineering from Worcester Polytechnic Institute and a Master of Management Science from the Massachusetts Institute of Technology’s Sloan School of Management.

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Baxter is a registered trademark of Baxter International Inc.

Contacts

Media Contact
Stacey Eisen, (224) 948-5353
media@baxter.com

Investor Contact
Clare Trachtman, (224) 948-3020

AMSTERDAM–(BUSINESS WIRE)–GEDi Cube, an AI/ML platform that combines differential molecular capabilities with multi-omic analysis to detect cancer at its earliest stage, is delighted to announce the appointment of Dr Lester Russell as Chief Medical Officer. A seasoned expert and leader in clinical medicine and digital health, Lester will be responsible for leading on clinician engagement, clinical validation, and clinical quality assurance as GEDi Cube transitions to the testing and go-to-market phase for its AI/ML platform.

“We are excited to have Lester join us at this critical juncture in the life of GEDi Cube,” said Craig Rhodes, Chief Executive Officer of GEDi Cube. “His long-term experience in the healthcare sector as well as expertise in the use of technologies to improve patient outcomes will be invaluable to us as we progress our solution for early detection of cancer and other diseases using AI and machine learning tools. We look forward to working with him and we are sure he will make a positive contribution.”

Lester brings over 40 years’ experience in clinical medicine and 23 years in digital health with experience ranging from senior roles in technology organisations, the public sector, and several successful start-ups. In his previous role at IBM as Clinical Lead in Health & Life Sciences, Systems AI, he spent two years building a new unit in artificial intelligence that focused on developing pioneering solutions.

Other experience includes senior positions in the health and life sciences units at Intel and Fujitsu. At Intel, Lester delivered multiple proof-of-concept research and development projects and assisted the sales team to achieve 150% of their target revenue. While at Fujitsu, Lester helped found a global healthcare community across the companies in the Fujitsu Group, with over 480 members.

“I am delighted and honoured to be joining the team at GEDi Cube to advance the fight against cancer and other diseases using novel technologies like artificial intelligence and cell-based therapies,” said Dr Lester Russell, Chief Medical Officer of GEDi Cube. “Improved detection and monitoring of diseases such as cancer is the next major frontier in healthcare and the potential to use techniques such as machine learning to improve survival is hugely exciting.

“I am also thrilled about the planned merger of GEDi Cube and Renovaro, which will mean that their proprietary cell-based therapy can be informed and honed by the insights gained from GEDi Cube’s machine learning platform. This truly represents a new and very promising method of providing a cancer vaccine that is both targeted, specific and effective in the fight against cancer, and possibly other diseases.”

GEDi Cube offers a proprietary tool that analyses genetics using explainable AI (XAI) to provide early and accurate cancer diagnosis. The multi-omics platform searches for individual biomarkers that are present even in asymptomatic patients, in a process that also involves the mining of biomarker panels.

The company has both technical and clinical validation of cohorts for lung cancer. GEDi Cube has in silico validated biomarker panels for 13 types of cancer and, through its advanced AI/Machine Learning platform with access to vast amounts of big data, its data mining techniques have resulted in the development of over 2,600 proprietary biomarker panels and counting.

Contacts

GEDi Cube
Karen Brink, Chief Growth Officer
pr@gedicube.com

Gracechurch Group
Harry Chathli, Claire Norbury
+44 (0)204 582 3500
gedicube@gracechurchpr.com

As the company approaches commercialization, CorVista Health recognizes the importance of enhancing its Board of Directors with specialized expertise in the field of cardiovascular care. Dr. Attebery’s significant contributions in reshaping the model of cardiovascular care delivery in the USA through his innovative leadership at organizations such as the American College of Cardiology and Cardiovascular Associates of America make him a highly valued addition to the board.

“Our shareholders, along with the leadership team of CorVista Health, are thrilled to have Tim join our Board of Directors,” said Don Crawford, President, and CEO of CorVista Health. “His insights and expertise will enrich our board, and I am confident that his vast experience in healthcare and leadership will be instrumental in driving our future growth and development.”

As a member of our board, Dr. Attebery will provide further guidance and governance, drawing from his deep understanding of the cardiovascular healthcare space. His involvement will additionally support CorVista Health as it enters the next phase of growth following FDA Breakthrough Designation for their pulmonary hypertension focused device.

“I believe CorVista Health can transform the way cardiovascular disease is diagnosed, particularly in underserved geographies and populations with the greatest need,” said Dr. Attebery. “Advancements in healthcare are essential to help improve the diagnosis of cardiovascular patients especially in rural areas, and CorVista’s innovative solution has the potential to make a tremendous impact to our healthcare system.”

About CorVista® Health

CorVista Health, Inc. is applying machine learning to develop a novel cardiac diagnostic platform, CorVista® System, with the aim of transforming cardiovascular care and the patient experience. For more information, visit corvista.com CorVista Health is dedicated to addressing the FDA’s call to action for leveraging health technologies to advance health equity, as presented by FDA Commissioner, Dr. Robert Califf. Particularly, the decline in life expectancy in rural areas has been cited as key evidence of disparate health outcomes. CorVista System has the potential to enable more equitable care by providing access to immediately actionable, high-quality cardiovascular status results in low-resource settings, where access to capital-intensive equipment and the qualified specialists needed to operate them may not be available. In this way, the CorVista System is uniquely positioned to advance the quality of care in rural and low-resource settings.

About CorVista® System

CorVista System is a non-invasive point-of-care solution that is intended to synchronously collect and apply machine learning to a patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting or exercise. Within minutes of the test, the CorVista® Analysis is available in a secure web portal to aid physicians in rapidly diagnosing and treating patients with suspected cardiovascular disease, answering important clinical questions to guide better treatment decisions. CorVista System is an investigational device limited by federal law to investigational use. CorVista System is not available for commercial distribution.

Contacts

Chris Bing Ernst
415.710.9445
cernst@corvista.com

PITTSBURGH–(BUSINESS WIRE)–#accountablecareorganizations–ThoroughCare, Inc., a leading digital care coordination organization that enables healthcare payers and providers to effectively deliver value-based care, today announced the appointment of Carol Helton as the company’s new Chief Revenue Officer. Helton brings more than two decades of experience in senior leadership at high growth healthcare companies to the ThoroughCare team. By bringing in Helton as Chief Revenue Officer, ThoroughCare aims to capitalize on its increased business momentum and demand for its platform, as more payers and providers look to maximize their value-based contracts.

“Carol brings significant expertise from her previous work in the healthcare technology field, as experienced first-hand by several members of the ThoroughCare team, that we feel will help push us to even further heights,” said Earl Hutz, Chief Operating Officer of ThoroughCare. “As our operational footprint and prospective client base continues to expand, Carol’s leadership will help us maximize the potential of the services we provide.”

Helton most recently served as Chief Growth & Product Officer at a care management company supporting virtual care and digital health. Her background includes executive-level leadership experience in sales at several technology organizations for over two decades. In joining ThoroughCare, Helton brings her advanced healthcare business proficiency in driving company growth and rapidly expanding its industry presence.

“I’m honored to join ThoroughCare at this transformative time for both the company and the industry,” Helton said. “ThoroughCare is uniquely positioned to meet the next generation Collaborative Care Model. ThoroughCare’s approach to provider-driven, payer-enabled collaborative care has already proven to be a winning proposition and I look forward to being a part of the momentous growth.”

ThoroughCare recently announced expansion to a new location in Pittsburgh’s North Side to allow for further operations growth and new hiring initiatives. As one of Inc. Magazine’s fastest-growing private companies in the United States and Pennsylvania, ThoroughCare offers competitive compensation, benefits, retirement planning, and career advancement opportunities. Explore open roles at www.thoroughcare.net/join-our-team.

About ThoroughCare

Founded in 2013, ThoroughCare provides digital care coordination solutions to over 600 care delivery organizations throughout the United States. ThoroughCare’s comprehensive care coordination, analytics, and mobile applications are designed to enable personalized health experiences, streamline value-based care delivery, and help identify the next best actions at critical moments. Learn more at: www.thoroughcare.net

Note to editors: For more information, news and perspectives from ThoroughCare, journalists and analysts may call 844-842-6422. Web links, telephone numbers and titles were correct at time of publication but may have changed.

Contacts

Vivek Subramany – Vice President, Marketing
844-842-6422
vsubramany@thoroughcare.net

“I’m delighted to join the tremendously talented team at VivoSense,” said Colin Bower, CEO. “For more than a decade, they have led pharma partners and enhanced clinical research through the adoption of sensor-driven endpoints. By matching our new clinical measures based on machine learning with growing sponsor demand for validated digital endpoints, we will materially facilitate the path to precision care for all patients. I’m also looking forward to working closely with Dudley and building upon the internal culture he has built and the respect he has garnered from our partners and in the clinical trial market at large.”

“We’re excited to have Colin join us as CEO and Director of VivoSense and drive the next phase of our development. Colin’s track record with global biopharma and biotech partners is extensive and admirable,” added Chris Garabedian, a VivoSense Board Member. “He has consistently worked to improve the speed, safety, and cost-effectiveness of clinical trials through the adoption of new technological solutions. Colin has demonstrated strong leadership to his teams and customers alike.”

“I am excited to welcome Colin to VivoSense,” Dudley Tabakin, Chief Product Officer, told us. “Colin is a proven leader with a deep understanding of the digital health technology industry. He has a track record of success in growing and leading businesses, and I am confident that he is the right leader to take VivoSense to the next level. Colin and I will be working together — combining our strengths to build on our company’s success in developing and delivering real-world digital clinical measures and taking the company to new heights.”

Bower is a leader in healthcare technology with more than a decade of experience developing leading digital health products and bringing them to market in the roles of founder, CEO, commercial leader, and director. He served as President and CEO of Clintara prior to its acquisition by Bracket (now Signant Health). His continued work with Bracket drove the commercial growth of their data capture and analytics platform and proved instrumental in the firm’s acquisition by Genstar Capital. Following this acquisition, Bower went on to found EMA Wellness, a data and machine learning platform, where he currently serves as Executive Chair. He has most recently served as Chief Growth Officer at Panalgo, a leading machine learning RWD analytics platform, seeing it through an acquisition by MMIT, a company held jointly by Welsh, Carson, Anderson & Stowe and Hg. Bower holds a BA from McGill University and a Master of Business Administration degree from the University of Chicago.

With a suite of complementary skills, Bower joins VivoSense to continue our mission of developing and validating real-world clinical measures from digital technologies and delivering these trusted measures as meaningful endpoints in regulated clinical trials. His expertise and skill in commercializing healthcare technology solutions will position VivoSense to reach more customers and impact more patients than ever with the high-quality, innovative work that has earned us our reputation as an industry leader.

About VivoSense

VivoSense, Inc. is an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data. We are focused on healthcare clinical trial research & care. VivoSense’s hypothesis-driven framework provides analytical and clinical validation leading to FDA approval. The proprietary VivoSense® software enables the creation and validation of novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials.

For more information, visit www.vivosense.com. We are on Twitter. Follow us @vivosense.

Contacts

Rob Wilson – Vice President of Marketing Strategy
rob.wilson@vivosense.com
Tel: +1 858-876-8486

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Verily, an Alphabet precision health technology company, today announced the appointment of Andrew Trister, MD, PhD as Chief Scientific Officer. Dr. Trister will be responsible for leading the company’s population health initiatives and will provide expertise across Verily’s portfolio as the company furthers its precision health strategy.

Dr. Trister is a distinguished scientific leader with two decades of experience leveraging new technologies to translate research into product, drive population health initiatives and increase access to care. He joins Verily from The Bill & Melinda Gates Foundation where he served as the Deputy Director of Digital Health and Artificial Intelligence. In this role, he led the Foundation’s development and investment in digital health and artificial intelligence to address global health inequities. He also served as a lead for the foundation’s COVID-19 pandemic response where he created a government and industry consortium to speed the development and uptake of molecular and antigen tests for use globally.

Prior to The Bill & Melinda Gates Foundation, Dr. Trister was a founding member of Apple’s Health team, where he led clinical research and machine learning with Apple partners. He was responsible for developing and executing studies to discover novel biomarkers for Alzheimer disease and leading population health management programs. Prior to Apple, he was a senior physician at Sage Bionetworks, where he designed and shipped ResearchKit, an open-source tool for large-scale clinical trials and developed infrastructure to share and collaborate on medical imaging.

“Andrew is an accomplished leader with a proven track record of leading transformative health technology initiatives at leading organizations focused on improving human health,” said Stephen Gillett, Chief Executive Officer at Verily. “His expertise in leveraging data and technology to improve access to care and outcomes will be critical as Verily advances our focus on precision health.”

“What excites me about Verily is the opportunity to join the company at such a pivotal time in its journey to better understand, prevent and treat disease at scale,” said Andrew Trister, MD, PhD. “I look forward to partnering with an incredible team of industry experts to close the gap between research and care and advance learnings at the individual level to impact larger populations.”

Dr. Trister’s appointment follows the recent senior leadership additions of Laura O’Donnell as General Counsel and Utpal Koppikar as Chief Financial Officer at Verily.

About Verily

Verily is an Alphabet health technology company focused on research, care and health financing to deliver on the promise of precision health and help people live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools to accelerate evidence generation, products to enable more personalized care, and approaches to make costs more predictable. For more information, please visit: verily.com.

Contacts

Steven Cooper
Head of Media Relations, Verily
sjcoop@verily.com